SYRE Stock Summary and Trading Ideas (Spyre Therapeutics | NASDAQ:SYRE)

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Spyre Therapeutics trades on the NASDAQ stock market under the symbol SYRE.

As of March 13, 2026, SYRE stock price declined to $39.89 with 826,208 million shares trading.

SYRE has a beta of 1.94, meaning it tends to be more sensitive to market movements. SYRE has a correlation of 0.27 to the broad based SPY ETF.

SYRE has a market cap of $3.13 billion. This is considered a Mid Cap stock.

Last quarter Spyre Therapeutics reported $0 in Revenue and -$.70 earnings per share. This fell short of revenue expectation by $-111,110 and exceeded earnings estimates by $.04.

The top ETF exchange traded funds that SYRE belongs to (by Net Assets): VTI, IWM, XBI, VXF, IBB.

SYRE has outperformed the market in the last year with a return of +121.2%, while the SPY ETF gained +21.4%. In the last 3 month period, SYRE beat the market returning +18.6%, while SPY returned -2.6%. However, in the most recent 2 weeks SYRE has underperformed the stock market by returning -7.3%, while SPY returned -3.5%.

SYRE support price is $38.90 and resistance is $41.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYRE shares will trade within this expected range on the day.